project id: TCGA-BLCA; case submitter id: TCGA-CU-A72E; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.83; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.5; rna integrity number: 7.3; age at index: 76; days to birth: -27963; days to death: 413; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Dead; year of birth: 1937; age at diagnosis: 27963; ajcc pathologic m: M0; ajcc pathologic n: N2; ajcc pathologic stage: Stage IV; ajcc pathologic t: T3b; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 284.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: yes; prior treatment: Yes; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: Not Reported; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; cigarettes per day: 3.7260273972602738; pack years smoked: 68.0; is ffpe: false; weight: 20.0; composition: Not Reported; days to collection: 197; days to sample procurement: 0; initial weight: 240.0; portion submitter id: TCGA-CU-A72E-01A-12; percent lymphocyte infiltration: 5.0; percent monocyte infiltration: 1.0; percent necrosis: 1.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 54.0; percent tumor cells: 45.0; percent tumor nuclei: 85.0;